{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-030726","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.400840+00:00","generated_at":"2026-06-05T04:14:58.129960+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Apogee reports positive Phase 1 data for APG777 with ~75-day half-life; FY2023 net loss $84M","bullets":["APG777 Phase 1 interim data: half-life ~75 days, deep pSTAT6 and TARC suppression for ~3 months, well tolerated.","Phase 2 in moderate-to-severe AD planned for 1H 2024; induction designed to exceed lebrikizumab exposures by 30-40%.","Cash $395.5M at Dec 31, 2023; expected runway into Q4 2026.","FY 2023 net loss $84.0M vs $39.8M from inception (Feb 2022) to Dec 2022; R&D expenses $68.4M.","APG808 (anti-IL-4Rα) Phase 1 trial starting ahead of schedule; Phase 2 in COPD expected 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-030726","json":"https://secwatch.observer/filing/0001104659-24-030726.json","markdown":"https://secwatch.observer/filing/0001104659-24-030726.md","text":"https://secwatch.observer/filing/0001104659-24-030726.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924030726/0001104659-24-030726-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924030726/tm247826d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:14:58.129960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}